newsfilter
← Latest News
GlobeNewswire·

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

Study did not meet key efficacy objectives Favorable safety profile consistent with prior studies, including with new 450mg loading dose and up to 300mgQ4W regimenProfound systemic mast cell depletion, as evidenced by